Loading…

Loading grant details…

Completed HORIZON European Commission

Innovative, minimally invasive Medical Prostatic Retraction Device for the treatment of Benign Prostatic Hyperplasia (BPH) Patients in the office settings.

€4.82M EUR

Funder European Commission
Recipient Organization Butterfly Medical Ltd
Country Israel
Start Date Sep 01, 2023
End Date Aug 31, 2025
Duration 730 days
Number of Grantees 1
Roles Coordinator
Data Source European Commission
Grant ID 190156124
Grant Description

Butterfly Medical, a medical-device start-up, is developing a fast, simple, and minimally invasive alternative treatment to medication and surgery used for Benign Prostate Hyperplasia (BPH) treatment.

Butterflys innovative device transfers the procedure from the operating room to the clinic, with the device being placed in 6 to 8 minutes, in doctors office, under local anaesthesia.

Butterflys unique anatomically shaped proprietary nitinol implant is positioned in the prostatic urethra in order to open the urine path in the prostate for improved urine flow thereby relieving BPH symptoms.

Implant doesnt require any resection, cutting, or ablation of prostatic tissue.FIH clinical trials involving 85 patients performed in leading medical centres in Israel show a high degree of safety and effectiveness.

Through this EIC project, Butterfly will undertake post-marketing studies in leading medical centres in Europe, and pivotal FDA study in the US.

All Grantees

Butterfly Medical Ltd

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant